Orthobiologics company Ossio closed a $38.5 million series C financing round.
The proceeds will help accelerate adoption of the Ossiofiber intelligent bone regeneration technology, CEO Brian Verrier said in an Oct. 17 news release. Money will also support new product development, sales force expansion, patient outreach and medical education.
Ossiofiber is designed for rapid bone ingrowth, regeneration and replacement. It has been implanted in more than 10,000 cases.
MVM Partners, a Boston-based growth equity firm, led financing.